Download Files:
Evofosfamide
$138 – $835
Products Details
Product Description
– Evofosfamide (TH-302) is a hypoxia-activated proagent with IC50 of 10 μM and 1000 μM in hypoxia (N2) and normoxia (21% O2), respectively.
Web ID
– HY-10535
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C9H16Br2N5O4P
References
– [1]Meng F, et al. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21;15:422.|[2]Zhang X, et al. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016 May 26;11(5):e0155289.|[3]Peeters SG, et al. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [<sup>18</sup>F]HX4 Hypoxia PET Imaging. Clin Cancer Res. 2015 Jul 1;21(13):2984-92.
CAS Number
– 918633-87-1
Molecular Weight
– 449.04
Compound Purity
– 98.0
SMILES
– O=P(NCCBr)(OCC1=CN=C(N1C)[N+]([O-])=O)NCCBr
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : 94 mg/mL (ultrasonic;warming)|H2O : 4.35 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Apoptosis
Pathway
– Apoptosis
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
